Related Experiment Video
Updated: Jan 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Follow-Up Lipid Testing and Statin Initiation Among Young Adults in a U.S. Health Care System
Teresa N Harrison1, Yiyi Zhang2, Soon Kyu Choi1
1Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Background:
More than 50% of U.S. young adults have low-density lipoprotein cholesterol (LDL-C) ≥100 mg/dL, and young adults are less likely to be aware of their high LDL-C levels compared with older age adults.
Objectives:
This study examined patterns of LDL-C testing and statin initiation following an initial elevated LDL-C measurement and assessed temporal trends of LDL-C testing and statin initiation from 2008 to 2018.
Methods:
We identified Kaiser Permanente Southern California members aged 18 to 39 years with their first elevated LDL-C measurement (index) between 2008 and 2020. We examined the proportion of young adults with a follow-up LDL-C test and statin initiation within 1, 2, and 5 years after the index LDL-C measurement, overall, and stratified by high-risk subgroups. We also assessed the temporal trends of follow-up LDL-C testing and statin initiation within 1 year of an elevated LDL-C measurement from 2008 to 2018 among high-risk subgroups: 1) LDL-C ≥190 mg/dL; and 2) LDL-C 160 to 189 mg/dL and high estimated 30-year atherosclerotic cardiovascular disease (ASCVD) risk.
Results:
Among 771,681 young adults, 65.9%, 25.3%, 6.9%, and 1.9% had an index LDL-C of 100 to 129 mg/dL, 130 to 159 mg/dL, 160 to 189 mg/dL, and ≥190 mg/dL, respectively. Among those with LDL-C ≥190 mg/dL, 28.4%, 33.5%, and 45.7% initiated a statin within 1, 2, and 5 years, respectively. The proportions of young adults with 30-year high ASCVD risk and LDL-C ≥160 to 189 mg/dL who initiated a statin were 25.3%, 31.9%, and 46.4% within 1, 2 and 5 years, and 44.1%, 50.2%, and 61.5% within 1, 2, and 5 years, respectively, among those with LDL-C ≥190 mg/dL. Follow-up LDL-C testing within 1 year declined between 2008 and 2018, from 52.5% to 35.4% among those with LDL-C 160 to 189 mg/dL and high 30-year risk. Statin initiation within 1 year also declined in both high-risk subgroups from 31.7% and 36.5% in 2008 to 20.1% and 12.6% in 2018.
Conclusions:
These findings suggest care gaps in lipid management of young adults with elevated LDL-C and represent missed opportunities to reduce cumulative LDL-C exposure and to prevent premature ASCVD during a critical window of vulnerability.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Coronary Artery Disease IV: Preventive Measures
